What question did this study set out to answer?

The aim is to compare the effectiveness and resistance outcomes of ceftazidime-avibactam and meropenem-vaborbactam in KPC-producing Enterobacterales infections.

March 25, 2026Open Access

Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections

Key Points

The aim is to compare the effectiveness and resistance outcomes of ceftazidime-avibactam and meropenem-vaborbactam in KPC-producing Enterobacterales infections.
Analyzed a cohort of 73 patients with KPC-producing Enterobacterales infections
Used propensity-score weighting to balance group characteristics
Assessed both mortality rates and emergence of resistance.
Thirty-day mortality rates were similar for both treatments
Resistance emerged more frequently in the ceftazidime-avibactam group (12% vs 0%)
Identified resistance mechanisms included porin mutations and structural changes in AmpC.

Abstract

Thirty-day mortality was similar in a propensity-score-weighted cohort of 73 patients with KPC-producing Enterobacterales infections treated with ceftazidime-avibactam or meropenem-vaborbactam. Emergence of resistance was higher in the ceftazidime-avibactam group (12% vs 0%); putative resistance mechanisms included porin mutations (Klebsiella pneumoniae) and R2 loop structural changes in AmpC (Enterobacter cloacae complex).

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Karaba et al. (Mon,) studied this question.

synapsesocial.com/papers/69c37be2b34aaaeb1a67eaaf https://doi.org/https://doi.org/10.1128/aac.01602-25

Bookmark

View Full Paper